Insulet Corporation, known for its innovative insulin delivery systems, holds a prominent position in the medical devices sector. With a strong product offering, the company has captured significant market share and continues to expand its presence internationally. However, careful analysis of its fundamental ratios provides insights into the financial strengths and potential areas of improvement.
The fundamental ratings suggest a balanced performance of Insulet Corporation, with room for improvement in key financial metrics.
Category | Score | Visualization |
---|---|---|
Overall | 2 | |
Discounted Cash Flow | 1 | |
Return on Equity | 5 | |
Return on Assets | 5 | |
Debt to Equity | 1 | |
Price to Earnings | 1 | |
Price to Book | 1 |
Comparing past and current scores reveals consistent financial performance, with minor improvements evident over time.
Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-05-02 | 2 | 1 | 5 | 5 | 1 | 1 | 1 |
Date Not Available | 0 | 1 | 5 | 5 | 1 | 1 | 1 |
Analyst price targets reflect optimism in market value, with a consensus leaning towards continued growth.
High | Low | Median | Consensus |
---|---|---|---|
322 | 270 | 300 | 297.33 |
Analyst recommendations predominantly favor a 'Buy' status, suggesting confidence in Insulet's market trajectory.
Recommendation | Count | Visualization |
---|---|---|
Strong Buy | 0 | |
Buy | 27 | |
Hold | 10 | |
Sell | 2 | |
Strong Sell | 0 |
Insulet Corporation's stock shows potential with a "Buy" recommendation from analysts, underpinned by strong demand for its innovative insulin delivery solutions. Despite some limitations in its financial metrics such as debt-to-equity and earnings ratios, the company's cutting-edge products and expanding geographical reach highlight significant growth opportunities. Investors should consider potential market challenges and the broader economic context while evaluating this stock for long-term investment.